No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported. SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE N ...
Moderna's growth story is just beginning.
Find the latest covid vaccine news from Fast company. See related business and technology articles, photos, slideshows and ...
Online content falsely claiming vaccines can be distributed through the food supply has circulated for years and a new series ...
Among healthy adults receiving the JN.1- or KP.2-adapted mRNA seasonal COVID-19 vaccine, neutralizing antibody responses were similar.
VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...
A comprehensive review found that mRNA vaccines are a resoundingly safe and effective feat of modern medicine.
A massive, global review of mRNA vaccines has shown that they are very effective and safe. Reporting in The Lancet, ...
From space to healthcare and artificial intelligence, what could the next 250 years of the United States look like?
FDA Advisors Back Moderna's mRNA Flu Vaccine Unanimously: The Biggest Healthcare Move of Summer 2026
Your resource for the hottest moving stocks and news. We cover all sectors and markets giving everyday investors access to ...
The FDA advisory panel unanimously supported mRNA-1010/mFLUSIVA for adults 50–64 and 65+, and the stock is already reacting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results